Literature DB >> 8038354

Rapid healing of gastric ulcers with lansoprazole.

K D Bardhan1, J Ahlberg, W S Hislop, C Lindholmer, R G Long, A G Morgan, S Sjostedt, P M Smith, R Stig, K G Wormsley.   

Abstract

BACKGROUND: Lansoprazole is a new proton pump inhibitor which powerfully decreases acid secretion.
METHODS: We compared the efficacy and short-term safety of lansoprazole against ranitidine in the healing of gastric ulcer. This was a parallel group, comparative multicentre, prospectively randomized, double-blind study which included 250 patients with gastric ulcer, 219 of whom had follow-up endoscopic data.
RESULTS: Both lansoprazole 30 mg and 60 mg daily produced significantly more rapid healing of gastric ulcer than ranitidine 300 mg nightly with healing rates after 4 weeks of 78% (P < 0.05), 84% (P < 0.01) and 61%, respectively. After 8 weeks, the corresponding healing rates were 99%, 97% and 91% (P = 0.08). Symptom relief was similar for all treatment groups, but fewer antacids were used by patients receiving lansoprazole. Sixty-nine patients experienced 91 adverse events; the incidence, pattern and severity was similar across all three treatment groups.
CONCLUSIONS: Lansoprazole 30 mg and 60 mg once daily had similar efficacy. Both were superior to ranitidine 300 mg nocte in healing gastric ulcer. The short-term safety profile of lansoprazole was similar to ranitidine. These data indicate that lansoprazole should be used at a dose of 30 mg once daily for the treatment of gastric ulcers.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8038354     DOI: 10.1111/j.1365-2036.1994.tb00281.x

Source DB:  PubMed          Journal:  Aliment Pharmacol Ther        ISSN: 0269-2813            Impact factor:   8.171


  11 in total

Review 1.  Lansoprazole. An update of its pharmacological properties and clinical efficacy in the management of acid-related disorders.

Authors:  H D Langtry; M I Wilde
Journal:  Drugs       Date:  1997-09       Impact factor: 9.546

2.  Short-term treatment of gastric ulcer. A meta-analytical evaluation of blind trials.

Authors:  F Di Mario; G Battaglia; G Leandro; G Grasso; F Vianello; S Vigneri
Journal:  Dig Dis Sci       Date:  1996-06       Impact factor: 3.199

3.  Double-blind comparison of lansoprazole 15 mg, lansoprazole 30 mg, and placebo in the maintenance of healed gastric ulcer.

Authors:  T O Kovacs; D Campbell; M Haber; P Rose; D E Jennings; J Richter
Journal:  Dig Dis Sci       Date:  1998-04       Impact factor: 3.199

Review 4.  Are the orally administered proton pump inhibitors equivalent? A comparison of lansoprazole, omeprazole, pantoprazole, and rabeprazole.

Authors:  A B Thomson
Journal:  Curr Gastroenterol Rep       Date:  2000-12

5.  Antioxidant defense of fish collagen peptides attenuates oxidative stress in gastric mucosa of experimentally ulcer-induced rats.

Authors:  Divya K Vijayan; P R Sreerekha; Pavan Kumar Dara; B Ganesan; Suseela Mathew; Rangasamy Anandan; C N Ravisankar
Journal:  Cell Stress Chaperones       Date:  2021-11-17       Impact factor: 3.827

Review 6.  pH, healing rate and symptom relief in acid-related diseases.

Authors:  J Q Huang; R H Hunt
Journal:  Yale J Biol Med       Date:  1996 Mar-Apr

7.  Determination of lansoprazole in biological fluids and pharmaceutical dosage by HPLC.

Authors:  A Avgerinos; T h Karidas; C Potsides; S Axarlis
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1998 Apr-Jun       Impact factor: 2.441

8.  Initial and chronic gastric acid inhibition by lansoprazole and omeprazole in relation to meal administration.

Authors:  R J Brummer; B J Geerling; R W Stockbrügger
Journal:  Dig Dis Sci       Date:  1997-10       Impact factor: 3.199

Review 9.  Lansoprazole. A reappraisal of its pharmacodynamic and pharmacokinetic properties, and its therapeutic efficacy in acid-related disorders.

Authors:  C M Spencer; D Faulds
Journal:  Drugs       Date:  1994-09       Impact factor: 9.546

10.  Are proton pump inhibitors the first choice for acute treatment of gastric ulcers? A meta analysis of randomized clinical trials.

Authors:  Maribel Salas; Alexandra Ward; Jaime Caro
Journal:  BMC Gastroenterol       Date:  2002-07-15       Impact factor: 3.067

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.